LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) a
molecular diagnostics company, is pleased to announce that today,
Dr. Jack Regan, CEO and Founder of LexaGene, will present at the
Biothreat and Pathogen Detection Conference regarding the MiQLab™
System’s ability to detect the pathogen that causes plague.
Dr. Jack Regan states, “Our MiQLab System is both open-access
and designed for point-of-care use, making it a
first-of-its-kind
system. These unique features are critical for early point-of-care
diagnoses, which improves the probability for successful
biocontainment of novel pathogens. The past 18 months have
highlighted how badly humanity needs advanced technologies like the
MiQLab to more successfully contain a novel pathogen capable of
causing a pandemic. MiQLab is uniquely suited to fill the massive
technology gap in our testing infrastructure as it has the
potential to drastically reduce the response time from initial
identification of a novel pathogen to the rapid deployment of new
detection tests at the point of care. Minimizing this response time
significantly improves the chances of successful pathogen
containment so that countless lives can be saved.”
A brief interview with Dr. Regan regarding LexaGene’s value
proposition for pandemic prevention can be viewed HERE.
The 28th International Biothreat and Pathogen Detection
Conference is an internationally recognized meeting for experts in
the detection and identification of biological threats. This
conference addresses key topics in pathogen detection and presents
the latest R&D and technological innovations in rapid pathogen
identification. In addition, this meeting focuses on the latest
strategies to overcome the hurdles surrounding the rapid
identification of global biological threats and bringing new
technologies from the lab to the field.
History is filled with numerous instances of naturally occurring
outbreaks of biothreat agents that have collectively killed 100s of
millions of people. Plague is arguably the deadliest pathogen of
all time. Other pathogens have also caused massive loss of life,
including the 1918 Influenza Pandemic, HIV, Ebola,1 and SARS-CoV-2.
Unfortunately, intentional use of biothreat agents have been
documented from the Middle Ages through both World Wars and even
into modern times.2 The most recent examples include the 1984
Salmonella bioterrorism attack in Oregon3 and the 2001 anthrax
letters.4
Plague has caused numerous pandemics in the human history.5 Due
to its history as a killer and the potential for plague to still
cause a large number of deaths and the difficulty of successful
containment, it is classified by the government as Category A
Bioterrorism agent.6
In order to demonstrate the MiQLab’s capabilities for biothreat
agent detection, LexaGene developed a plague test and completed an
analytical evaluation with contrived samples.
Dr. Regan comments, “I’m extremely pleased with the quality of
our plague test. In silico analysis showed close to 100% coverage
of all plague genomes. Analytical studies showed our test to
correlate extremely closely with quantitative culture (R2 >
0.94). Our test is also very sensitive, as we were able to reliably
detect levels 1000-fold lower than levels of this bacterium
commonly detected in the blood of infected patients.7 Lastly, in an
exclusivity study, our test did not cross react with any of the
tested phylogenetically related microorganisms. These high-quality
test results are a testament to the MiQLab’s capabilities as a
surveillance and detection tool when faced with a natural or
intentional biothreat.”
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing, and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately two
hours. The unique open-access feature is designed for custom
testing so that end-users can load their own real-time PCR assays
onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
[1] Walper SA, et al. Detecting biothreat agents: from current
diagnostics to developing sensor technologies. ACS Sens.
2018;3:1894–2024.
[2] Riedel, S. Biological Warfare and Bioterrorism: A Historical
Review. BUMC Proc. 2004, 17, 400−406.
[3] https://www.foodsafetynews.com/2009/10/for-the-first-12/
[4]
https://www.npr.org/2011/02/15/93170200/timeline-how-the-anthrax-terror-unfolded
[5] https://en.wikipedia.org/wiki/Pandemic
[6] https://emergency.cdc.gov/agent/agentlist-category.asp
[7] Montminy, S., Khan, N., McGrath, S. et al. Virulence factors
of Yersinia pestis are overcome by a strong lipopolysaccharide
response. Nat Immunol 7, 1066–1073 (2006).
https://doi.org/10.1038/ni1386
Investor Contact:
ir@lexagene.com
800.215.1824
Media Contact:
Gail Winslow
Director of Corporate Marketing
gwinslow@lexagene.com
978.482.6237
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024